Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe
Ann Oncol
.
2021 Jan;32(1):12-14.
doi: 10.1016/j.annonc.2020.10.481.
Epub 2020 Oct 27.
Authors
L Meza
1
,
P G Bergerot
2
,
N Agarwal
3
,
S K Pal
4
Affiliations
1
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA.
2
Department of Medical Oncology, Cettro Cancer Center, Brasilia, Brazil.
3
Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, USA.
4
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA. Electronic address: spal@coh.org.
PMID:
33121996
DOI:
10.1016/j.annonc.2020.10.481
No abstract available
Publication types
Editorial
Comment
MeSH terms
Carcinoma, Renal Cell* / drug therapy
Humans
Kidney Neoplasms* / drug therapy
Nivolumab
Phenylurea Compounds
Quinolines
Substances
Phenylurea Compounds
Quinolines
tivozanib
Nivolumab